← All stocks

Innoviva, Inc.

INVA Net selling
CIK 0001080014 #2241 in the set updated 18 Sep 2026
Bought (120 mo)
$8.77M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$422.45M
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$422.45M
28 of 28 sales
Net
−$413.68M
−$413.68M against sales at will

By person

27 insiders · 43 transactions
8.3×

Pavel Raifeld holds 8.3 times base salary in stock. $4.99M of shares against $600.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Pavel Raifeld last reported holding, valued at $17.52, the price Common Stock, par value $0.01 per share was last bought or sold at on the open market here, on 6 Mar 2025.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
GSK plc entity
10% owner
$392.06M (1)
−$392.06M
0
0.0000%
$0.00
−100.0%
DENNER ALEXANDER J
10% owner
$7.98M (9)
$28.40M (3)
−$20.42M
5,658,705
7.83%
$99.13M
−14.9%
Bickerstaff George
Director
$651.75K (4)
+$651.75K
137,207
0.1899%
$2.40M
Witek Theodore J. Jr.
Sr. VP & Chief Scientific Off.
$591.00K (5)
−$591.00K
247,767
0.3430%
$4.34M
+54.7%
dEsparbes Eric
SVP and CFO
$460.94K (8)
−$460.94K
373,081
0.5164%
$6.54M
+54.4%
ABERCROMBIE GEORGE B
Sr. VP & Chief Comm. Officer
$429.29K (4)
−$429.29K
285,479
0.3952%
$5.00M
+63.6%
Zhen Marianne
Chief Accounting Officer
$350.17K (6)
−$350.17K
56,389
0.0781%
$987.81K
+49.9%
Aguiar Michael W
President & Chief Exec Officer
$157.79K (1)
−$157.79K
980,907
1.36%
$17.18M
+41.5%
HULME GEOFFREY
Interim Principal Exec Officer
$103.60K (1)
+$103.60K
49,751
0.0689%
$871.52K
+177.0%
Raifeld Pavel
Chief Executive Officer
$32.60K (1)
+$32.60K
284,799
0.3942%
$4.99M
+2,866%
Faerm Michael E.
Sr VP & Chief Business Officer
279,422
0.3868%
$4.89M
+68.7%
WALTRIP WILLIAM H
Director
161,789
0.2239%
$2.83M
+14.0%
Haimovitz Jules
Director
152,692
0.2114%
$2.67M
+1,152%
DiPaolo Mark
Director
140,492
0.1945%
$2.46M
Schlesinger Sarah J.
Director
140,492
0.1945%
$2.46M
Odysseas Kostas D
Director
122,625
0.1697%
$2.15M
Basso Stephen
Chief Financial Officer
88,013
0.1218%
$1.54M
FRIEDMAN CATHY
Director
73,805
0.1022%
$1.29M
+36.8%
PEPE PAUL
Director
73,805
0.1022%
$1.29M
+36.8%
Tyree James L
Director
70,554
0.0977%
$1.24M
+39.2%
Birx Deborah
Director
58,984
0.0816%
$1.03M
+448.8%
LEPORE PATRICK G
Director
58,278
0.0807%
$1.02M
DUNCAN BARBARA GAYLE
Director
52,318
0.0724%
$916.49K
Small Derek A
Director
45,035
0.0623%
$788.91K
+386.9%
Srivastava Sapna
Director
44,096
0.0610%
$772.46K
+222.4%
Ronsheim Matthew
See Remarks
40,510
0.0561%
$709.64K
+33.2%
Linden Josephine
Director
15,194
0.0210%
$266.16K

Nothing of that kind in this period.

What was left out

Form 4 filings counted 190
Amendments (4/A) skipped 6
Filings about a different issuer 13
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 28
Transactions with no price 0
Shares from compensation/vesting 2,883,418
Sales filed before the plan box existed 23
History held since 27 Oct 2016